Related Experiment Videos
[Allergic skin rashes by methylprednisolone in a case with multiple sclerosis]
Atsushi Kuga1, Naonobu Futamura, Itaru Funakawa
1Department of Neurology, National Hospital Organization Hyogo Chuo National Hospital.
Rinsho Shinkeigaku = Clinical Neurology
|December 1, 2004
Summary
A multiple sclerosis patient experienced an allergic reaction to methylprednisolone sodium succinate. Betamethasone substitution therapy successfully resolved neurological symptoms and MRI findings without adverse effects.
Area of Science:
- Neurology
- Clinical Immunology
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Methylprednisolone sodium succinate is a common treatment for acute MS relapses.
- Allergic reactions to corticosteroids, though rare, can complicate treatment.
Observation:
- A 34-year-old female with MS presented with neurological deficits indicative of an acute relapse.
- She developed a widespread skin rash following the initiation of methylprednisolone sodium succinate pulse therapy.
- A positive patch test confirmed an allergic reaction to methylprednisolone sodium succinate.
Findings:
- The patient's allergic reaction necessitated a change in treatment from methylprednisolone sodium succinate.
- Intravenous betamethasone administration (100mg/day for three days) was initiated as a substitute therapy.
- Neurological symptoms and MRI-detected lesions resolved completely following betamethasone treatment.
Implications:
- This case highlights the potential for allergic reactions to methylprednisolone sodium succinate in MS patients.
- Betamethasone serves as an effective alternative treatment option for MS relapses in patients with corticosteroid hypersensitivity.
- Substitution therapy with betamethasone offers a safe and efficacious approach to managing MS exacerbations when methylprednisolone is contraindicated.